Although PD-1/PD-L1 mAbs have obtained positive results in some clinical trials, most of the benefited groups are only those with high PD-L1 CPS score, MSI-H, or high tumor mutational burden (TMB) (44), and it has also been reported that patients with Epstein–Barr virus (EBV)–positive tumors can respond significantly to anti–PD-1 antibody (55). The gene discussed is PDCD1; the disease is neoplasm.